Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Vicki L. Goodman"'
Autor:
Patricia Haney, Michelle Casey, Keith T. Flaherty, Anne O'Hagan, Ademi Santiago-Walker, Dirk Schadendorf, Vicki L. Goodman, Axel Hauschild, Jeffrey J. Legos, Richard F. Kefford, Robert C. Gagnon, Patrick Hwu, Jolly Mazumdar, Anne-Marie Martin, Georgina V. Long, Jennifer Carver
Publikováno v:
Clinical Cancer Research. 22:567-574
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Autor:
Vanna Chiarion-Sileni, Michael Millward, J.-J. Grob, Kelly M. Grotzinger, Salvador Martín-Algarra, Boguslawa Karaszewska, Vicki L. Goodman, Lev V. Demidov, Mayur M. Amonkar, Suzanne Swann, Patricia Haney, E. Kämpgen, Wilson H. Miller, Axel Hauschild, Piotr Rutkowski, Cornelia Mauch, Beloo Mirakhur
Publikováno v:
Annals of Oncology. 25:1428-1436
Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18–0.53; P < 0.0001) compared with dacarbazine (DTIC) i
Autor:
Anne O'Hagan, Ekaterina Gibiansky, Daniele Ouellet, Julie Switzky, Vicki L. Goodman, Patricia Haney, Cathrine Leonowens
Publikováno v:
The Journal of Clinical Pharmacology. 54:696-706
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. The population pharmacokinetics of dabrafenib, including changes over time and relevant covariates, were characterized based on results from f
Autor:
Salomon M. Stemmer, Vicki L. Goodman, Michael Durante, Stephen R. D. Johnston, Maria Richie, Henry L. Gomez, Lini Pandite, Dennis J. Slamon
Publikováno v:
Breast Cancer Research and Treatment. 137:755-766
This phase II study (VEG20007; NCT00347919) with randomized and open-label components evaluated first-line lapatinib plus pazopanib therapy and/or lapatinib monotherapy in patients with human epidermal growth factor receptor type 2 (HER2)-positive ad
Autor:
Christian U. Blank, Jean-Jacques Grob, Paul B. Chapman, Vicki L. Goodman, Cornelia Mauch, Anne-Marie Martin, Michael Millward, Eckhart Kaempgen, Lev V. Demidov, Wilson H. Miller, Axel Hauschild, Thomas Jouary, Piotr Rutkowski, Salvador Martín-Algarra, Suzanne Swann, Ralf Gutzmer, Patricia Haney, Mary E. Guckert, Beloo Mirakhur, Vanna Chiarion-Sileni, Boguslawa Karaszewska
Publikováno v:
The Lancet. 380:358-365
Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAF V600 -mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients
Autor:
Vincent Mooser, Lon R. Cardon, Chun-Fang Xu, Zhengyu Xue, Lini Pandite, Brian H. Reck, Colin F. Spraggs, Lingkang Huang, Beena T. Koshy, Vicki L. Goodman, Michael R. Barnes
Publikováno v:
Journal of Hepatology. 54:1237-1243
Background & Aims Pazopanib has demonstrated clinical benefit in patients with advanced renal cell carcinoma (RCC) and is generally well tolerated. However, transaminase elevations have commonly been observed. This 2-stage study sought to identify ge
Autor:
Jogarao V. S. Gobburu, Edwin P. Rock, Cheng Yi Liang, Sophia Abraham, Nallaperumal Chidambaram, S. Leigh Verbois, David E. Morse, Janet X. Jiang, Shenghui Tang, Richard Pazdur, Robert Justice, Roshni Ramchandani, Vicki L. Goodman, Ramzi Dagher, Brian Booth, Kooros Mahjoob
Publikováno v:
Clinical Cancer Research. 13:1367-1373
Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to i
Autor:
Bo Ma, Aung Naing, Martin Curtis, Vicki L. Goodman, Maria E. Cabanillas, Sarina Anne Piha-Paul, Gerald S. Falchook, David S. Hong, Michael Millward, Steven G. Waguespack, Razelle Kurzrock, Steven I. Sherman
Publikováno v:
Thyroid : official journal of the American Thyroid Association. 25(1)
Mutations of v-raf murine sarcoma viral oncogene homolog B (BRAF) are commonly identified in papillary and anaplastic thyroid carcinoma and are associated with worse prognosis compared with the wild type. BRAF inhibition in papillary thyroid carcinom
Autor:
Daniele, Ouellet, Ekaterina, Gibiansky, Cathrine, Leonowens, Anne, O'Hagan, Patricia, Haney, Julie, Switzky, Vicki L, Goodman
Publikováno v:
Journal of clinical pharmacology. 54(6)
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. The population pharmacokinetics of dabrafenib, including changes over time and relevant covariates, were characterized based on results from f
Autor:
Julie Switzky, Dirk Schadendorf, Tabea Wilhelm, Mary E. Guckert, Richard F. Kefford, Vicki L. Goodman, Laurent Mortier, Paul B. Chapman, Michael R. W. Streit, Lisa Zimmer, Suzanne Swann, Georgina V. Long, Alain Algazi, Uwe Trefzer, Anne-Marie Martin, Caroline Robert, Michael A. Davies, Igor Puzanov, John M. Kirkwood, Hussein Tawbi, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
The Lancet. Oncology. 13(11)
Summary Background Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metas